Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have earned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $14.30.

Several analysts have recently commented on VNDA shares. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, June 4th. Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Truist Financial started coverage on Vanda Pharmaceuticals in a research report on Thursday, March 5th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th.

Vanda Pharmaceuticals Trading Down 0.8%

Shares of VNDA stock opened at $5.95 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15. The company has a market cap of $357.77 million, a price-to-earnings ratio of -1.47 and a beta of 0.62. Vanda Pharmaceuticals has a 1 year low of $4.14 and a 1 year high of $9.94. The firm has a fifty day moving average price of $6.44 and a 200-day moving average price of $7.08.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The company had revenue of $51.72 million during the quarter, compared to analysts’ expectations of $54.98 million. As a group, equities analysts predict that Vanda Pharmaceuticals will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several large investors have recently made changes to their positions in VNDA. Torren Management LLC purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Vanda Pharmaceuticals by 3,010.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 10,055 shares during the last quarter. Jain Global LLC bought a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at approximately $94,000. Finally, Quarry LP purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $53,000. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.